As described in the European Medicines Agency's European Public Assessment Report (EPAR), it works by enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
While rare, cancers in the stomach or colon can cause bleeding
Less common, but more severe side effects that have been reported include gallbladder and pancreas problems
When skin loses its collagen and elasticity then you see wrinkles, fine lines, sagging skin, etc
According to recent research, the risk of major infant congenital malformations is not increased when using second-line noninsulin antidiabetic medications like GLP-1 receptor agonists, as compared to using insulin
Semaglutide GLP-1 may be prescribed to manage type 2 diabetes or for weight loss purposes